TapImmune Provides Fourth Quarter and Year-End 2017 Corporate and Clinical Update

JACKSONVILLE, Fla., April 5, 2018 /PRNewswire/ --Recent Corporate and Clinical Developments: Published long-term immune response and progression-free survival data from completed Phase 1 clinical study of TPIV200 Commenced dosing in 280-patient, grant-funded Phase 2...